Bortezomib

Aetna covers bortezomib for specified indications — including acute lymphoblastic leukemia; adult T‑cell leukemia/lymphoma as a single agent for subsequent therapy; Kaposi sarcoma as subsequent therapy; antibody‑mediated solid‑organ rejection; relapsed/refractory follicular lymphoma; and (where applicable) multiple myeloma (precertification required). All other uses are considered experimental/investigational (per the policy’s long exclusion list), and coverage requires dosing limits of ≤1.6 mg/m2 per dose and no more than seven doses per 30‑day period, with precertification for multiple myeloma obtained via the plan’s phone/fax.

"Pediatric classic Hodgkin lymphoma - relapsed or refractory disease"

Sign up to see full coverage criteria, indications, and limitations.